Cancer scientists say they have engineered a new type of super-strong antibody which could be used to boost the immune systems of patients fighting the disease.

Experts from the University of Southampton altered the shape and flexibility of the tiny proteins, which are naturally produced by white blood cells to protect the body from bacteria and viruses.

They discovered that their antibody prototype, which was more rigid, was able to trigger a stronger response from the immune system compared to those made by our bodies.

Their study, which was funded by Cancer Research UK, has been published in the journal Nature Communications.

Professor Mark Cragg, from the Centre for Cancer Immunology at the University of Southampton, said: "The concept of using immuno-stimulation for cancer treatment is very exciting.

“Our study confirms that making even subtle increases in the rigidity of antibodies significantly stimulates immune activity, creating a powerful immune response against the disease.

“This approach works for multiple antibodies targeting different immune receptors.

“The ability to engineer these rigid antibodies could help develop more potent drugs that can stimulate the immune system to target cancer or other diseases.”

The Y-shaped antibodies fight infections by targeting and then binding onto molecules on the surface of bacteria and viruses, or even cancerous cells.

They can also be engineered to attach to receptors on immune cells to activate our body’s immune defences.

But not all antibodies do this effectively, said study co-author Isabel Elliott, a PhD student from Southampton.

She added: “The shape and flexibility of antibodies is crucial for how well they can activate immune cells – and we found more rigid antibodies seem to be better at this.

“The reason for this is likely because these rigid antibodies can hold molecules on the immune cells closer together, which triggers a stronger activation signal.

“Floppier antibodies are less likely to do this effectively.”

The two arms of antibodies, which give its Y shape, are linked by a series of bridges, named disulfide bonds.

The Southampton scientists managed to add extra bridges between the microscopic arms of the antibodies and tested it against standard variants.

Dr Ivo Tews, a Professor in Structural Biology at Southampton, added: “We used a supercomputer to visualise the structure of the antibody in atomic detail, allowing us to position extra disulfide bonds in the modified antibody.

“The results showed that the experiment worked and that the new, more rigid antibodies were more effective at activating immune cells.

“This idea of controlling antibody activity by making them more rigid seems to apply to many other similar molecules on immune cells.”

Executive Director of Research and Innovation at Cancer Research UK, Dr Iain Foulkes, said: “Refining our understanding of how to enable our immune systems to fight cancer is a complex but fundamental step in helping cancer patients to have the best chance of a good outcome when receiving immunotherapy treatment.

“Using the latest technologies to engineer this type of super-strong antibody that could trigger a promising immune response will empower us to continue pioneering new ways to outsmart cancer.”

Read the paper at www.nature.com/articles/s41467-025-58773-8.

ENDS

NOTES TO EDITORS

• Structure-guided disulfide engineering restricts antibody conformation to elicit TNFR agonism

• Published in Nature Communications

• DOI: 10.1038/s41467-025-58773-8

Logo

Tags

More Like This

ImmunAbs Announces Conclusion of Phase 1 Clinical Trial, Revealing Positive Topline Results

Mestag Therapeutics Enlists Leading Cancer Biology and Immunology Advisors to Support Clinical Development of its Lead Oncology Program

Epsilogen Announces Acquisition of TigaTx, Inc. to Create World’s Leading Pan-Isotype Cancer Antibody Company

New T-FINDER Platform Provides Deep Insights Into T Cell Responses Against Novel Cancer Vaccine

Cancer trial: retraining immune cells offers new hope for patients in personalized medicine breakthrough

IGI Announces Publication in Nature Cancer on ISB 2001, IGI's Innovative Trispecific Antibody for Relapsed/Refractory Multiple Myeloma

New Immuno-Oncology Research Project in Partnership With Merck Starts at the BioMed X Institute in Heidelberg

NeoMab Fully Human Antibody Discovery Platform: A New Flexible Mouse Purchase Model Leading a New Trend in Antibody Drug Development